Nurix Therapeutics Inc Forecast, price target & analysts
Nurix Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Nurix Therapeutics Inc Classifications & Recommendation
Nurix Therapeutics Inc Price Target
| Target Price | $34.68 |
| Price | $25.50 |
| Potential |
36.00%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Nurix Therapeutics Inc 2027 .
The average Nurix Therapeutics Inc target price is $34.68.
This is
36.00%
register free of charge
$47.25
85.29%
register free of charge
$25.25
0.98%
register free of charge
|
|
| A rating was issued by 21 analysts: 19 Analysts recommend Nurix Therapeutics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Nurix Therapeutics Inc stock has an average upside potential 2027 of
36.00%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Nov '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 83.98 | 66.78 |
| 53.95% | 20.49% | |
| EBITDA Margin | -329.76% | 282.26% |
| 11.70% | 185.60% | |
| Net Margin | -314.91% | -416.87% |
| 11.26% | 32.38% |
18 Analysts have issued a sales forecast Nurix Therapeutics Inc 2026 . The average Nurix Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Nurix Therapeutics Inc EBITDA forecast 2026. The average Nurix Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Nurix Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Nurix Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Nov '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.05 | -2.68 |
| 5.90% | 12.13% | |
| P/E | negative | |
| EV/Sales | 32.99 |
18 Analysts have issued a Nurix Therapeutics Inc forecast for earnings per share. The average Nurix Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Nurix Therapeutics Inc...
Current Nurix Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jul 28 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Jul 22 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jul 10 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 10 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jul 28 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Jul 22 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jul 10 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 10 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
